Simulations Plus, Inc.

318 articles with Simulations Plus, Inc.

• Simulations Plus Announces Quarterly Cash Dividend of $0.06 per Share - Oct. 14, 2019

  10/14/2019

  Simulations Plus, Inc. announced that its board of directors has declared its next ongoing quarterly cash dividend of $0.06 per share of the Company’s common stock.

• Simulations Plus Announces Leadership Changes at Cognigen

  10/2/2019

  Jill Fiedler-Kelly named President along with other promotions and key additions

• Simulations Plus Partners with Clinical-Stage Biotech Company to Develop Novel Dosing Models

  9/4/2019

  New intra-articular injection route will expand the suite of drug delivery options available in GastroPlus®

• Simulations Plus Enters into New Research Collaboration Agreement with the FDA

  7/16/2019

  Center for Veterinary Medicine to apply GastroPlus® to assess product bioequivalence in canines

• Simulations Plus Reports Third Quarter FY2019 Financial Results

  7/10/2019

  Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today reported financial results for its third quarter of fiscal year 2019 (3QFY19) and the first nine months of fiscal year 2019 (9moFY19), the period ended May 31, 2019.

• Simulations Plus Upgrades PKPlus™

  7/9/2019

  Enhancements include improved data handling and command line functionality

• Simulations Plus Sets Date for 3rd Quarter 2019 Earnings Release and Conference Call

  7/2/2019

  Conference Call to be on Wednesday, July 10, 2019, at 4:15 PM ET

• DILIsym Releases NAFLDsym® Version 2A

  6/27/2019

  Substantial update of NAFLD drug efficacy software offers a broad range of pathophysiology and over a thousand simulated patients for testing

• Simulations Plus Upgrades Flagship GastroPlus

  6/18/2019

  User- and collaboration-driven functionality in version 9.7 expands the science of local and systemic exposure

• PMDA Adds Licenses of GastroPlus®

  5/21/2019

  Japanese government organization to train reviewers to efficiently analyze PBPK model submissions

• U.S. FDA Renews DILIsym Software Licenses

  5/16/2019

  U.S. FDA Remains Committed to Streamline & Accelerate Drug Development using Model-Informed Drug Development (MIDD) technology

• Simulations Plus to Present at B. Riley FBR Investor Conference on May 22, 2019

  5/14/2019

  Simulations Plus, Inc. announced that Shawn O’Connor, chief executive officer, will present at the 20th Annual B. Riley FBR Institutional Investor Conference on Wednesday, May 22, at 10:30 a.m. (PDT) in Room 8.

• Lisa LaVange, PhD, Appointed to Board of Directors of Simulations Plus

  5/1/2019

  Simulations Plus, Inc. (Nasdaq:SLP), the premier provider of simulation and modeling software and consulting services for all stages of pharmaceutical discovery and development, today announced the appointment of Dr. Lisa LaVange to the Company’s Board of Directors.

• FDA Purchases Bundle of ADMET Predictor® Licenses

  4/30/2019

  Simulations Plus, Inc. (Nasdaq:SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has received an order from the U.S. Food and Drug Administration (FDA) for a 15-user license to its ADMET Predictor® software suite.

• Simulations Plus Releases ADMET Predictor® Version 9.5

  4/11/2019

  New machine learning models and novel analysis methods address customer requests

• Simulations Plus Reports Record Second Quarter FY2019 Revenue

  4/9/2019

  Simulations Plus, Inc. (Nasdaq:SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today reported financial results for its second quarter of fiscal year 2019, the period ended February 28, 2019 (2QFY19).

• Simulations Plus Sets Date for 2nd Quarter 2019 Earnings Release and Conference Call

  4/2/2019

  Conference Call to be on Tuesday, April 9, 2019, at 4:15 PM ET

• DILIsym Awarded $1.5 Million Phase II NIH Grant

  1/17/2019

  Phase II Award of NIH Fast Track SBIR Grant for Drug-induced Kidney Injury Software, RENAsym™, Funds Development Over Next 20 Months

• Simulations Plus Releases DDDPlus™ Version 6

  1/15/2019

  New models for in vitro systems lead to improved inputs for GastroPlus® simulations

• Simulations Plus to Present at the 21st Annual Needham Growth Conference

  1/10/2019

  Mr. O’Connor will host one-on-one meetings throughout the day at the conference which will be held at the Lotte New York Palace Hotel.